Mereo BioPharma (MREO) Share-based Compensation (2021 - 2026)

Mereo BioPharma (MREO) has reported Share-based Compensation for 6 consecutive years, with $19.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Share-based Compensation rose 39.66% year-over-year to $19.8 million in Q2 2026; TTM through Jun 2026 was $19.8 million, a 39.66% increase from a year earlier, with the FY2025 full-year figure at $13.5 million, up 19.58% from the prior year.
• Share-based Compensation was $19.8 million for Q2 2026 at Mereo BioPharma, roughly flat from $19.9 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $19.9 million in Q1 2026 and troughed at $815000.0 in Q4 2023.
• A 5-year average of $8.8 million and a median of $11.3 million in 2024 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation sank 89.87% in 2023 and surged 1130.62% in 2024, its largest moves.
• Over 5 years, Share-based Compensation stood at $8.0 million in 2022, then slumped by 89.87% to $815000.0 in 2023, then surged by 85.89% to $1.5 million in 2024, then climbed by 1.85% to $1.5 million in 2025, then surged by 1185.27% to $19.8 million in 2026.
• The last three Share-based Compensation figures came in at $19.8 million (Q2 2026), $19.9 million (Q1 2026), and $1.5 million (Q4 2025), per Business Quant data.